News & Updates
Filter by Specialty:

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
byStephen Padilla
Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Chemo plus atezolizumab improves survival while preserving life quality in advanced EC
19 Aug 2024
byStephen Padilla
Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.